This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Strategos/wRatings Innovation Index Identifies The Most Innovative Pharmaceutical And Medical Device Companies

Innovaro (NYSE Amex: INV), a comprehensive innovation solution company, and The wRatings Corporation, an independent stock research firm, today announced the results of their quarterly Strategos/wRatings Innovation Index, with the focus of this issue on the pharmaceutical and medical device industry. The study was conducted as a collaborative effort between Innovaro Strategos, a strategic services business of Innovaro, and The wRatings Corporation.

This quarter’s results show the pharmaceutical and medical device industry lags other industries in innovation. This finding is the latest and perhaps most compelling evidence for the demise of the industry’s prevailing blockbuster drug business model.

The biggest investors in research and development, pharmaceutical and medical device companies have not been recognized for innovation. Compared with recent analyses of innovation performance of food & beverage and consumer electronics companies, the industry performed poorly. The average index scores of the top 10 performers is 46 (out of 100), whereas the averages of the top 10 for food & beverage and consumer electronic industries are 76 and 84, respectively.

The Blockbuster Drug Business Model Is Being Challenged

A review of top pharmaceutical and medical device companies shows a collection of companies that have developed and continue to develop wondrous drugs and medical devices, saving and improving the quality of millions of lives. Developments include treatments for HIV, heart failure, hepatitis C, Alzheimer's, Huntington's, cancer and other complex medical conditions. However, as demonstrated by our analysis and echoed by the CBO report indicting the industry has substantially lower R&D productivity than other R&D intensive industries 1, indiscriminately pouring resources into R&D may not be the best route for optimizing shareholder returns.

“Innovation is more than invention,” states Peter Skarzynski, Senior Managing Director of Innovaro Strategos and author of Innovation to the Core (HBSP, 2008). “As the industry faces seismic changes caused by new regulations, demographic shifts, and consumerism, companies that can successfully challenge industry orthodoxies and innovate at the level of the business model have the best chance of thriving.”

“The blockbuster drug model has worked well for pharmaceutical and medical device companies and their investors,” explains Gary A. Williams, CEO and Founder of wRatings. “Going forward, it’s becoming clearer that they will need to apply their creative energy to developing revolutionary business models in addition to inventing revolutionary drugs and devices in order to improve their ranks in innovation.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
INV $0.14 0.00%
AUXL $36.47 -0.16%
BDX $137.12 -0.09%
COV $106.71 -1.26%
EW $146.27 0.68%


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs